Lundbeck TOMs Orthostatic Hypotension
Primary Purpose
Orthostatic Hypotension, Idiopathic Parkinson Disease
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Droxidopa 100 MG [Northera]
Sponsored by
About this trial
This is an interventional other trial for Orthostatic Hypotension
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of idiopathic Parkinson's Disease, meeting UK Brain Bank criteria for at least 3 years
- Hoehn and Yahr (H&Y) stage I-III
- Age between 30 and 80 years old (both inclusive)
- Stable dosage of dopaminergic medications for at least 4 weeks
- Orthostatic Hypotension, defined as a fall in systolic BP ≥ 20 mmHg or diastolic BP ≥ 10 mmHg within 3 minutes of standing
- Willingness and ability to comply with scheduled visits
Exclusion Criteria:
- Diabetes mellitus or other diseases potentially associated with autonomic dysfunction
- Treatment with antihypertensive drugs or with alpha-adrenergic antagonists
- Cognitive impairment, defined as a score < 24 at the Montreal Cognitive Assessment (MoCA)
- Any atypical signs lowering the diagnostic certainty for PD
- Lack of postural reflex defined as a score > 2 at the MDS-UPDRS item 3.12 (recover at the pull test)
- Severe levodopa induced dyskinesia, defined as an MDS-UPDRS item 4.2 > 2 (functional impact of dyskinesia)
Sites / Locations
- University of Cincinnati
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Droxidopa
Arm Description
100-600mg droxidopa TID
Outcomes
Primary Outcome Measures
Orthostatic Hypotension Questionnaire (OHQ) Score
Orthostatic Hypotension Symptom Assessment (OHSA; Range: 0-10) and Orthostatic Hypotension Daily Activities Scale (OHDAS; Range: 0-10) 10 items measured on a Likert-scale with 10 being the worst possible score.
Tinetti Score
he Tinetti assessment tool is an easily administered task-oriented test that measures an older adult's gait and balance abilities. Scoring: Items are scored either "0-1" or "0-2". "0" indicates the highest level of impairment, whereas a higher score (1 or 2) indicates the individuals independence.
There were 17 tasks (one task split into two sub-items and scored twice) that the scores were summed for a highest possible score of 28 (10 items scored on a 0-1 scale, and 8 items scored on a 0-2 scale).
The Tinetti assessment was compared pre- and post- 6 week medication dosing.
PDQ-39 Score
The Parkinson's Disease Questionnaire (PDQ-39) assesses how often people with Parkinson's experience difficulties across 8 dimensions of daily living including mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort.
The scale consists of 39 items ranked on a 5-point ordinal scale (Never=0, Occasionally=1, Sometimes=2, Often=3, Always=4).
Each dimension total score range from 0 (never have difficulty) to 100 (always have difficulty). Lower scores reflect better Quality of Life.
Dimension score = sum of scores of each item in the dimension divided by the maximum possible score of all the items in the dimension, multiplied by 100.
Overall score = sum of dimension total scores divided by 8.
Scores were compared pre- and post- 6 weeks dosing with medication.
Gait Analysis - Stride Length
Measured in cm
Gait Analysis - Single Leg Stance Time
Using a gait mat, participants were instructed to walk self-paced along the mat. The sensors in the mat automatically extracted the percentage of time a participant stood on a single leg. The output was compared pre- and post- 6 week dosing with study medication.
Gait Analysis - Gait Velocity
Using a gait mat, participants were instructed to walk self-paced on the mat, turn around, and walk back. Their velocity was measured in cm/sec.
This output was compared pre- and post- 6 week dosing with study medication.
Postural Analysis - Postural Sway
Using a gait mat, postural sway was measured in cm on the X-axis while participants were asked to stand eyes open and eyes closed for 30 seconds. This output was compared pre- and post- 6 weeks dosing with study medication.
Secondary Outcome Measures
Full Information
NCT ID
NCT04510922
First Posted
July 9, 2020
Last Updated
August 30, 2022
Sponsor
Alberto Espay, MD, MSc
Collaborators
Lundbeck LLC
1. Study Identification
Unique Protocol Identification Number
NCT04510922
Brief Title
Lundbeck TOMs Orthostatic Hypotension
Official Title
Technology-Based Objective Measures for Gait and Postural Assessment in Parkinson Disease Patients With Orthostatic Hypotension: Feasibility and Effect-Size Finding Study
Study Type
Interventional
2. Study Status
Record Verification Date
August 2022
Overall Recruitment Status
Completed
Study Start Date
February 11, 2019 (Actual)
Primary Completion Date
December 31, 2020 (Actual)
Study Completion Date
December 31, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Alberto Espay, MD, MSc
Collaborators
Lundbeck LLC
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Orthostatic hypotension (OH), which consists in a significant reduction in blood pressure levels upon standing from a seated position, may affect approximately one in three patients with Parkinson's disease (PD). It usually presents as dizziness, lightheadedness, feeling faint, or feeling like you might black out while standing. This can significantly impact the quality of life (QoL) of PD patients, resulting in difficulties with balance, walking, and increased risk of falls. The main aim of this study is to evaluate whether the use of technological devices (a computerized system for analyzing abnormalities in walking in clinical settings and a wearable sensor to detect changes in postural unsteadiness in the home environment) may improve the detection of complications and the response to medical therapies for OH in patients with PD.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Orthostatic Hypotension, Idiopathic Parkinson Disease
7. Study Design
Primary Purpose
Other
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
9 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Droxidopa
Arm Type
Experimental
Arm Description
100-600mg droxidopa TID
Intervention Type
Drug
Intervention Name(s)
Droxidopa 100 MG [Northera]
Intervention Description
droxidopa taken three times a day titrated up to a maximum of 600 mg.
Primary Outcome Measure Information:
Title
Orthostatic Hypotension Questionnaire (OHQ) Score
Description
Orthostatic Hypotension Symptom Assessment (OHSA; Range: 0-10) and Orthostatic Hypotension Daily Activities Scale (OHDAS; Range: 0-10) 10 items measured on a Likert-scale with 10 being the worst possible score.
Time Frame
1 month
Title
Tinetti Score
Description
he Tinetti assessment tool is an easily administered task-oriented test that measures an older adult's gait and balance abilities. Scoring: Items are scored either "0-1" or "0-2". "0" indicates the highest level of impairment, whereas a higher score (1 or 2) indicates the individuals independence.
There were 17 tasks (one task split into two sub-items and scored twice) that the scores were summed for a highest possible score of 28 (10 items scored on a 0-1 scale, and 8 items scored on a 0-2 scale).
The Tinetti assessment was compared pre- and post- 6 week medication dosing.
Time Frame
6 weeks
Title
PDQ-39 Score
Description
The Parkinson's Disease Questionnaire (PDQ-39) assesses how often people with Parkinson's experience difficulties across 8 dimensions of daily living including mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort.
The scale consists of 39 items ranked on a 5-point ordinal scale (Never=0, Occasionally=1, Sometimes=2, Often=3, Always=4).
Each dimension total score range from 0 (never have difficulty) to 100 (always have difficulty). Lower scores reflect better Quality of Life.
Dimension score = sum of scores of each item in the dimension divided by the maximum possible score of all the items in the dimension, multiplied by 100.
Overall score = sum of dimension total scores divided by 8.
Scores were compared pre- and post- 6 weeks dosing with medication.
Time Frame
6 weeks
Title
Gait Analysis - Stride Length
Description
Measured in cm
Time Frame
1 month
Title
Gait Analysis - Single Leg Stance Time
Description
Using a gait mat, participants were instructed to walk self-paced along the mat. The sensors in the mat automatically extracted the percentage of time a participant stood on a single leg. The output was compared pre- and post- 6 week dosing with study medication.
Time Frame
6 weeks
Title
Gait Analysis - Gait Velocity
Description
Using a gait mat, participants were instructed to walk self-paced on the mat, turn around, and walk back. Their velocity was measured in cm/sec.
This output was compared pre- and post- 6 week dosing with study medication.
Time Frame
6 weeks
Title
Postural Analysis - Postural Sway
Description
Using a gait mat, postural sway was measured in cm on the X-axis while participants were asked to stand eyes open and eyes closed for 30 seconds. This output was compared pre- and post- 6 weeks dosing with study medication.
Time Frame
6 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of idiopathic Parkinson's Disease, meeting UK Brain Bank criteria for at least 3 years
Hoehn and Yahr (H&Y) stage I-III
Age between 30 and 80 years old (both inclusive)
Stable dosage of dopaminergic medications for at least 4 weeks
Orthostatic Hypotension, defined as a fall in systolic BP ≥ 20 mmHg or diastolic BP ≥ 10 mmHg within 3 minutes of standing
Willingness and ability to comply with scheduled visits
Exclusion Criteria:
Diabetes mellitus or other diseases potentially associated with autonomic dysfunction
Treatment with antihypertensive drugs or with alpha-adrenergic antagonists
Cognitive impairment, defined as a score < 24 at the Montreal Cognitive Assessment (MoCA)
Any atypical signs lowering the diagnostic certainty for PD
Lack of postural reflex defined as a score > 2 at the MDS-UPDRS item 3.12 (recover at the pull test)
Severe levodopa induced dyskinesia, defined as an MDS-UPDRS item 4.2 > 2 (functional impact of dyskinesia)
Facility Information:
Facility Name
University of Cincinnati
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
21571570
Citation
Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Bie RM. Prevalence of orthostatic hypotension in Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2011 Dec;17(10):724-9. doi: 10.1016/j.parkreldis.2011.04.016. Epub 2011 May 14.
Results Reference
background
PubMed Identifier
25678194
Citation
Palma JA, Gomez-Esteban JC, Norcliffe-Kaufmann L, Martinez J, Tijero B, Berganzo K, Kaufmann H. Orthostatic hypotension in Parkinson disease: how much you fall or how low you go? Mov Disord. 2015 Apr 15;30(5):639-45. doi: 10.1002/mds.26079. Epub 2015 Feb 12.
Results Reference
background
PubMed Identifier
9408097
Citation
Senard JM, Rai S, Lapeyre-Mestre M, Brefel C, Rascol O, Rascol A, Montastruc JL. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997 Nov;63(5):584-9. doi: 10.1136/jnnp.63.5.584.
Results Reference
background
PubMed Identifier
10101555
Citation
Tan LC, Tan AK, Tjia HT. The profile of hospitalised patients with Parkinson's disease. Ann Acad Med Singap. 1998 Nov;27(6):808-12.
Results Reference
background
PubMed Identifier
15884038
Citation
Woodford H, Walker R. Emergency hospital admissions in idiopathic Parkinson's disease. Mov Disord. 2005 Sep;20(9):1104-8. doi: 10.1002/mds.20485.
Results Reference
background
PubMed Identifier
19744137
Citation
Vossius C, Nilsen OB, Larsen JP. Parkinson's disease and hospital admissions: frequencies, diagnoses and costs. Acta Neurol Scand. 2010 Jan;121(1):38-43. doi: 10.1111/j.1600-0404.2009.01239.x. Epub 2009 Sep 10.
Results Reference
background
PubMed Identifier
22045363
Citation
Kaufmann H, Malamut R, Norcliffe-Kaufmann L, Rosa K, Freeman R. The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res. 2012 Apr;22(2):79-90. doi: 10.1007/s10286-011-0146-2. Epub 2011 Nov 2.
Results Reference
background
PubMed Identifier
27641792
Citation
Merola A, Romagnolo A, Rosso M, Lopez-Castellanos JR, Wissel BD, Larkin S, Bernardini A, Zibetti M, Maule S, Lopiano L, Espay AJ. Orthostatic hypotension in Parkinson's disease: Does it matter if asymptomatic? Parkinsonism Relat Disord. 2016 Dec;33:65-71. doi: 10.1016/j.parkreldis.2016.09.013. Epub 2016 Sep 10.
Results Reference
background
PubMed Identifier
25894561
Citation
Hubble RP, Naughton GA, Silburn PA, Cole MH. Wearable sensor use for assessing standing balance and walking stability in people with Parkinson's disease: a systematic review. PLoS One. 2015 Apr 20;10(4):e0123705. doi: 10.1371/journal.pone.0123705. eCollection 2015.
Results Reference
background
PubMed Identifier
3944402
Citation
Tinetti ME. Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc. 1986 Feb;34(2):119-26. doi: 10.1111/j.1532-5415.1986.tb05480.x. No abstract available.
Results Reference
background
PubMed Identifier
9351479
Citation
Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing. 1997 Sep;26(5):353-7. doi: 10.1093/ageing/26.5.353.
Results Reference
background
PubMed Identifier
7951684
Citation
Robbins TW, James M, Owen AM, Sahakian BJ, McInnes L, Rabbitt P. Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia. 1994 Sep-Oct;5(5):266-81. doi: 10.1159/000106735.
Results Reference
background
PubMed Identifier
23668316
Citation
Karrasch M, Laatu S, Martikainen K, Marttila R. CERAD test performance and cognitive impairment in Parkinson's disease. Acta Neurol Scand. 2013 Dec;128(6):409-13. doi: 10.1111/ane.12138. Epub 2013 May 14.
Results Reference
background
PubMed Identifier
27125836
Citation
Espay AJ, Bonato P, Nahab FB, Maetzler W, Dean JM, Klucken J, Eskofier BM, Merola A, Horak F, Lang AE, Reilmann R, Giuffrida J, Nieuwboer A, Horne M, Little MA, Litvan I, Simuni T, Dorsey ER, Burack MA, Kubota K, Kamondi A, Godinho C, Daneault JF, Mitsi G, Krinke L, Hausdorff JM, Bloem BR, Papapetropoulos S; Movement Disorders Society Task Force on Technology. Technology in Parkinson's disease: Challenges and opportunities. Mov Disord. 2016 Sep;31(9):1272-82. doi: 10.1002/mds.26642. Epub 2016 Apr 29.
Results Reference
background
PubMed Identifier
2841426
Citation
Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745-52. doi: 10.1136/jnnp.51.6.745.
Results Reference
background
PubMed Identifier
16930356
Citation
Lahrmann H, Cortelli P, Hilz M, Mathias CJ, Struhal W, Tassinari M. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol. 2006 Sep;13(9):930-6. doi: 10.1111/j.1468-1331.2006.01512.x.
Results Reference
background
PubMed Identifier
26502768
Citation
Dineen J, Freeman R. Autonomic Neuropathy. Semin Neurol. 2015 Aug;35(4):458-68. doi: 10.1055/s-0035-1558983. Epub 2015 Oct 6.
Results Reference
background
PubMed Identifier
15817019
Citation
Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x. Erratum In: J Am Geriatr Soc. 2019 Sep;67(9):1991.
Results Reference
background
PubMed Identifier
11927799
Citation
Jordan J, Biaggioni I. Diagnosis and treatment of supine hypertension in autonomic failure patients with orthostatic hypotension. J Clin Hypertens (Greenwich). 2002 Mar-Apr;4(2):139-45. doi: 10.1111/j.1524-6175.2001.00516.x.
Results Reference
background
PubMed Identifier
19025984
Citation
Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N; Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15;23(15):2129-70. doi: 10.1002/mds.22340.
Results Reference
background
PubMed Identifier
9827613
Citation
O'Sullivan JD, Said CM, Dillon LC, Hoffman M, Hughes AJ. Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function. Mov Disord. 1998 Nov;13(6):900-6. doi: 10.1002/mds.870130607.
Results Reference
background
Learn more about this trial
Lundbeck TOMs Orthostatic Hypotension
We'll reach out to this number within 24 hrs